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OBJECTIVES: To evaluate the relative likelihood of severe cutaneous reactions 
(Steven-Johnson Syndrome, toxic epidermal necrolysis), aseptic meningitis, and 
organ dysfunction (pancreatitis, hepatotoxicity) associated with antiepileptic 
drugs (AEDS) in children (aged 2-18 years) as compared to adults (aged 19+) with 
epilepsy. METHODS: This retrospective cohort study analyzed patients in a large 
nationally representative administrative claims database between 2006 and 2011. 
The sample consisted of Medicaid, Medicare, and Commercial patients with a 
diagnosis of epilepsy (ICD-9-CM 345.X) who were continuously enrolled with 
pharmacy benefits for 6-months and had no prior AEDS fills (new users). 
Multivariate analysis (logistic regression) was used to follow eligible patients 
from index date to first adverse event or up to six months after AED initiation. 
RESULTS: The study population included 1,803,871 new users of AEDS. Children 
comprised 7.9% (N=142,874, female=50.7%, age=12.4 [± 4.7]) and adults 92.1% 
(N=1,660,997, female=64.6%, age=52.8 [± 17.7]). Compared to adults, children were 
significantly less likely to experience organ dysfunction (OR=0.228, 95% CI: 0.20-
0.26, p<0.0001), but more likely to have severe cutaneous reactions (OR=1.19, 95% 
CI: 1.14-1.25, p<0.0001) after controlling for potential confounders (gender, 
region, type of medication). There was no significant age effect on risk of aseptic 
meningitis. Female adults had a statistically lower likelihood of organ 
dysfunction compared to males (OR=0.75, 95% CI: 0.72-0.77, p<0.0001), but there 
was no gender effect for risk of organ dysfunction in children. Females in both 
groups had a higher likelihood of developing cutaneous reactions compared to 
males (adults: OR=1.28, 95% CI: 1.25-1.31, p<0.0001; children: OR=1.20, 95% CI: 
1.15-1.26, p<0.0001). CONCLUSIONS: Adverse effects resulting from treatment 
with AEDS are an important consideration in evaluating epilepsy treatment 
options. This study provides new information about the comparative risks of 
AEDS that can be used to guide optimal prescribing practices for patients with 
epilepsy.  
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OBJECTIVES: To assess the comparative risk of adverse effects (AEs) across 
common treatment regimens for Parkinson’s disease (PD) in a large, real-world 
population. METHODS: Retrospective analyses were conducted using the 
MarketScan database, an employer-based source of inpatient, outpatient, and 
pharmacy claims for >30 million lives. Patients had ≥1 PD diagnosis (ICD-9-CM 
332.0) during 2000-2011 and ≥1 of the following anti-PD regimens: levodopa 
monotherapy (L-dopa), dopamine agonist monotherapy (DA), anticholinergic 
monotherapy (AC), L-dopa+DA, MAOB-inhibitor monotherapy (MAOB),  
L-dopa+COMT-inhibitor (L-dopa+COMT), L-dopa+AC, L-dopa+MAOB, or 
amantadine monotherapy (AMTD). Index groups were assigned based on first 
regimen exposed to. Patients had ≥6 months pre-index plan enrollment and were 
followed from index until AE or earliest of new regimen start, disenrollment, or 
database end. Cox models were estimated for each AE with covariates for index 
regimen (reference: MAOB), demographics, and pre-index comorbidities and AEs. 
RESULTS: 41,652 patients met the inclusion criteria (mean[SD] age: 73.4[11.0] 
years, 57.5% male). Index regimen distribution was: L-dopa (n=28,249), DA 
(n=7,775), AC (n=1,496), L-dopa+DA (n=578), MAOB (n=1,498), L-dopa+COMT 
(n=343), L-dopa+AC (n=106), L-dopa+MAOB (n=198), AMTD (n=1,409). AC,  
L-dopa+AC, and AMTD carried increased dyskinesia risk versus MAOB (hazard 
ratios (HRs) [95% CIs]: 2.1[1.8-2.5 ], 1.7[1.1-2.7], and 1.9[1.6-2.2], respectively).  
L-dopa+DA and L-dopa+MAOB had increased risk of orthostatic hypotension 
(HRs: 2.2[1.4-3.5] and 2.5[1.3-5.0]). L-dopa+DA carried the highest edema risk (HR: 
2.1[1.6-2.6]). L-dopa+DA and AMTD had increased risk of hallucinations (HRs: 
2.6[1.3-5.1] and 3.0[1.8-4.8]). For 6 of 9 AEs examined, L-dopa+DA had 
significantly (p<0.05) increased risk versus MAOB; in 4 of these (orthostatic 
hypotension, edema, nausea, hallucinations), L-dopa+DA carried the highest or 
second highest HR versus MAOB amongst all regimens examined. 
CONCLUSIONS: Treatments with high dopaminergic levels (L-dopa+DA) 
generally carried increased AE risk versus MAOB monotherapy. However, other 
dopamine-containing and non-dopaminergic regimens also carried increased AE 
risk versus MAOB. These findings highlight practical challenges presented by 
current PD treatments.  
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OBJECTIVES: To evaluate incidence of adverse effects (AEs) commonly associated 
with Parkinson’s disease (PD) and its treatments in a large, real-world 
population. METHODS: Retrospective analyses were conducted using the 
MarketScan database, an employer-based sourced of inpatient, outpatient, and 
pharmacy claims for >30 million lives (2000–2011). Inclusion criteria were ≥1 PD 
diagnosis (ICD-9-CM 332.0) and ≥30 days exposure to ≥1 of the following 
regimens: levodopa monotherapy (L-dopa), dopamine agonist monotherapy (DA), 
anticholinergic monotherapy (AC), L-dopa+DA, MAOB-inhibitor monotherapy 
(MAOB), L-dopa+COMT-inhibitor (L-dopa+COMT), L-dopa+AC, L-dopa+MAOB, 
amantadine monotherapy (AMTD). Patients were followed on AEs (defined by 
ICD-9-CM diagnoses) over all observed regimen exposures. Analyses were 
descriptive. RESULTS: In total, 87,373 patients were identified for inclusion 
(mean [SD] age 72.8 [10.9] years, 56.8% male). L-dopa was the largest cumulative 
exposure (80,246 person-years [PYs]), followed by L-dopa+DA (19,871 PYs) and DA 
(18,324 PYs). Dyskinesia incidence varied by treatment, ranging from 68/1,000 
PYs for L-dopa+MAOB to 492/1,000 PYs for AC. Orthostatic hypotension was 
higher in 5 of the 6 dopamine-containing regimens (64, 47, 45, 31, 25 per 1,000 
PYs for L-dopa+COMT, L-dopa+MOAB, L-dopa, L-dopa+DA, and DA, respectively) 
versus 2 of the 3 non-dopaminergic regimens (18, 19, 32 per 1,000 PYs for AC, 
MAOB, and AMTD). Edema incidence was highest during DA (215/1,000 PYs) and 
L-dopa+DA (192/1,000 PYs) exposures. Somnolence was highest, by far, during 
DA exposure (201 per 1,000 PYs); L-dopa+DA had the next highest somnolence 
incidence (115 per 1,000 PYs). Incidence of psychoses was high for all regimens 
(range: 202/1,000 PYs for L-dopa+MAOB to 3,500/1,000 PYs for AC). Abnormal 
dreaming/sleep attacks and impulse control disorders were not observed in this 
population, indicating a lack of coding for these conditions in routine practice. 
CONCLUSIONS: AE incidence during anti-PD treatment exposure varies by 
specific regimen. Some AEs, such as orthostatic hypotension, appear to be lower 
in non-dopaminergic monotherapies.  
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OBJECTIVES: To determine the frequency and economic impact of comorbid 
cardiac conditions among hospitalizations of patients with a diagnosis  
of multiple sclerosis (MS). METHODS: A retrospective analysis was conducted 
using the National Inpatient Sample (NIS), Healthcare Cost and Utilization 
Project, Agency for Healthcare Research and Quality. All hospital discharges  
with an MS diagnosis (ICD-9 CM 340.xx) from 1/1/2009 to 12/31/2009 were 
identified. Two cohorts were defined based on the presence or absence of at least 
one cardiac condition using ICD-9-CM codes: myocardial infarction (410.xx), 
ischemic disease (411.xx), angina (413.xx), occlusion of cerebral arteries (434.xx), 
acute cardiovascular disease (436.xx), cerebral ischemia (435.xx), and heart 
failure (428.xx). Total mean charges were converted to costs using NIS 2009 cost-
to-charge ratios. Total costs per discharge were compared between cohorts while 
controlling for demographics, number of chronic comorbidities, and length  
of stay (LOS). Descriptive statistics, t tests, and chi square tests were conducted 
where appropriate, and regression models were employed for cost comparisons. 
An incremental cost effectiveness ratio (ICER) was calculated for the cost per 
additional hospital day. RESULTS: A total of 27,463 discharges with a diagnosis of 
MS were identified, and 9.1% (n=2,522) had at least one cardiac comorbidity. The 
sample was 70% female with a mean age of 53.5 years. MS discharges with a 
cardiac condition were for patients with a significantly higher mean age (62.5 vs 
50.5 years, P<0.0001), more chronic comorbidities (7.8 vs 4.7 conditions, P<0.0001), 
and a longer LOS (6.4 vs 5.2 days, P<0.0001). The cost of hospitalization  
was significantly higher for MS discharges with a cardiac comorbidity after 
controlling for confounders ($16,752 vs $10,549, P<0.0001). The incremental  
cost per hospital day was $5,375 for discharges with a cardiac condition. 
CONCLUSIONS: Cardiac comorbidities are prevalent among MS discharges  
and are associated with higher costs than discharges without a cardiac 
comorbidity.  
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OBJECTIVES: To identify clinical and demographic predictors of urgent health 
care services utilization in monotherapy-treated patients with epilepsy. 
METHODS: Patients aged 18-64 years with a primary or secondary diagnosis of 
epilepsy and >1 prescription claim for an antiepileptic drug (AED) pre-index  
were included. Innovus Invision™ Data Mart insurance claims from January 1, 
2007 to September 30, 2010 were retrospectively analyzed. The primary outcome 
was incidence of seizures defined as an occurrence of an emergency room visit, 
ambulance service use or hospitalization with a primary or secondary diagnosis 
of epilepsy during the 1-year follow-up. Predictor variables included AED 
adherence, general comorbidity, any mental health comorbidity, evidence  
of a prior seizure, type of epilepsy diagnosis, presence of AED-interacting 
medications and any bioequivalent AED switch. The covariates included  
age, gender and geographic region of residence. RESULTS: The overall incidence 
of post-index seizures in the 1-year follow-up for four monotherapy cohorts 
combined was 5.3 % (n=166/3140). The combined cohort analysis demonstrated 
that pre-index seizures (odds ratio [OR] = 4.28; 95% CI, 2.81-6.53), any mental 
health comorbidity ([OR] = 3.41; 95% CI, 2.10-5.54), Charlson Comorbidity Index ≥1 
([OR] = 2.88; 95% CI, 1.96-4.24) and monotherapy with levetiracetam ([OR] = 1.54; 
95% CI, 1.03-2.31) were significant predictors of seizure recurrence. Among 
covariates, only geographic region was a significant predictor, with patients 
residing in the Northeast U.S. having higher odds of post-index seizure ([OR] = 
1.92; 95% CI, 1.19-3.10), while controlling for clinical, medication and 
demographic characteristics. A bioequivalent AED switch, type of epilepsy 
diagnosis, AED adherence and presence of interacting medications were  
not significant predictors of seizure recurrence (p>0.05). CONCLUSIONS: Results 
indicate that epilepsy patients with comorbid conditions (both mental  
and somatic diseases), as well as patients who may have initially been  
unstable (with previous seizure occurrences) were more likely to experience 
seizures.  
